An uncontrolled trial of clomipramine (Anafranil) in the treatment of phobic and obsessional states in general practice.
A small, open, multicentre trial of clomipramine (Anafranil, Geigy Pharmaceuticals) in the management of phobic and obsessional states was performed in general practice. New rating devices were used. Twenty-seven patient suffering from a variety of phobias and obsessions were treated with doses of clomipramine up to a maximum of 225 ng daily for six weeks. In phobic subjects best results were obtained in social phobias, agoraphobia and diffuse phobic anxiety, situational anxiety, interference, avoidance and autonomic effects all responding. An improvement of between 33% and 47% was seen in obsessional symptoms.
D000328:Adult; D000379:Agoraphobia / Q000188:drug therapy*; D002997:Clomipramine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003984:Dibenzazepines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000523:psychology; D010698:Phobic Disorders / Q000188:drug therapy* / Q000523:psychology
D003984:Dibenzazepines; D002997:Clomipramine